Blog & Resources Camargo Blog September 27th, 2007

CNN Story on “Unapproved Drugs”

CNN ran a story today to increase public awareness that there are hundreds of drugs consumed in the U.S. that have never been formally approved by the FDA. For professionals, the FDA has a web page devoted to this topic. Some of these products were subject to the DESI review process, but it is well known that producers have departed from these products in regards to strength and composition. As the CNN story points out, producers have added unapproved indications; for instance, quinine being promoted for leg cramps. 505(b)(2) is the most likely approval route for some of these drugs. However, most of these drugs are produced by low-cost, high-volume manufacturers and the time and cost of a 505(b)(2) is often prohibitive. We suggest that this represents an opportunity for the shrewd investor.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights